The COVID-RASi Trial (COVID-19)

  • End date
    Dec 26, 2022
  • participants needed
  • sponsor
    Ottawa Heart Institute Research Corporation
Updated on 26 June 2021
heart failure
myocardial infarction


The COVID-RASi study is an international randomized clinical trial that will evaluate the potential benefit of angiotensin modulators on clinical outcomes, in COVID-19 patients who are at high-risk for cardiovascular disease. The purpose of this study is to determine if renin-angiotensin system inhibitors (RASi), with angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARB), has a beneficial effect in high-risk older patients with COVID-19 infections, by reducing ICU admission, ventilator requirement or death. We would also like to determine if there are differences between ACEi and ARB therapeutic treatments.

Condition cardiovascular disorders, cardiovascular disease (cvd), *COVID-19, Covid-19, cardiovascular system diseases, Cardiovascular Disease, cardiovascular diseases
Treatment Angiotensin converting enzyme inhibitor, Angiotensin II Receptor Blockers, Angiotensin II Receptor Blockers
Clinical Study IdentifierNCT04591210
SponsorOttawa Heart Institute Research Corporation
Last Modified on26 June 2021


Yes No Not Sure

Inclusion Criteria

Patient with COVID-19 diagnosis with laboratory confirmation within the last 30 days AND
Age 65 years old or greater if outpatient OR age over 40 years old if inpatient (admitted to the hospital) at time of recruitment

Exclusion Criteria

Contraindication to ARB or ACEi, including severe aortic stenosis and angioedema
Patients who are currently on active treatment with ARB/ACEi
Known bilateral renal artery stenosis
Systolic BP 90 mmHg
eGFR<30 ml/min, if not receiving dialysis treatment
K>5.5 mmol/L on screening laboratory testing
Recent history of dizziness, vertigo, or orthostatic hypotension
Acute respiratory distress syndrome requiring invasive ventilation
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note